Skip to content

Involvement of the Translation Initiation Factors in Resolution of Inflammation in the Elderly Population

The Involvement of the Translation Initiation Factors eIF4E and eIF4G in Resolution of Inflammation in the Elderly Population

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02519361
Enrollment
30
Registered
2015-08-10
Start date
2015-08-31
Completion date
2016-01-31
Last updated
2015-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection in the Elderly

Keywords

elderly, immune response, acute infection

Brief summary

Aging cause specific changes in the immune system. Processes like immunoessence and inflammaging offend the functioning of the immune cells and expose the elderly patient to infections that can lead to morbidity and death. Protein translation regulation offers a strategic advantage to the immune cells, because it enables rapid activation or termination of synthesis of specific proteins, required for inflammation or its resolution. Translation initiation depends on recruitment of eukaryotic initiation factor eIF4F complex. The aim of the current study is to investigate the involvement of the translation initiation factors (eIF4E and eIF4G) in the process of recovery from acute infection in elderly patient admitted to the internal department with an acute infection.

Detailed description

1. Blood samples of elderly patients diagnosed with acute infection (fever and leukocytosis) will be collected twice - at admittance to Meir hospital and after recovery (24-48 hours without fever and leukocytosis). evidence of infection (chest x ray, urine and blood samples) will be collected. participants will be divided to two age groups: 65-80 yrs and very old patient \>85 yrs, and will be compared to younger patients aged 50-65. 2. Peripheral blood samples will be separated to subpopulations of lymphocytes, monocytes and polymorphonuclears, and protein will be extracted. 3. protein lysates will be separated by SDS-PAGE electrophoresis and immunoblotted for phosphorylated and total eIF4E and eIF4G; their regulators: Mnk 1/2, 4EBP1, mTOR and targets: cyclin D1, c-Myc, survivin, BCL2, VEGFA, etc. 4. Paired samples (within each age group) will be analyzed and correlated with clinical response of the patients. The source of the infection will also be considered. 5. Comparison between age groups at admittance and upon recovery will be made (Unpaired).

Interventions

None listed

Sponsors

Meir Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient aged 50 y and more with: * fever \>38c that started in the 48 hours prior to admission * leukocytosis \>10.0 K/microLiter * suspected source of infection by symptoms, lab results or imaging * treatment with antibiotics started in the last 24 hours or is about to be started

Exclusion criteria

* patients who cannot sign the informed concent ( dementia) * patients with active malignancy * patients who are under chemotherapy

Design outcomes

Primary

MeasureTime frameDescription
Translation initiation factors expression by immunoblotting, in leukocytes sub population1 weekAssessment of eIF4E and eIF4G expression by immunoblotting, in leukocytes sub populations under inflamed conditions and upon resolution of acute inflammation, in three groups of age

Secondary

MeasureTime frameDescription
Translation initiation factors regulators expression by immunoblotting in leukocytes sub population1 weekAssessment of eIF4E and eIF4G regulators expression by immunoblotting, in leukocytes sub populations under inflamed conditions and upon resolution of acute inflammation in three age groups
Translation initiation factors targets expression by immunoblotting in leukocytes sub population1 weekAssessment of eIF4E and eIF4G targets expression by immunoblotting in leukocytes sub populations under inflamed conditions and upon resolution of acute inflammation, in three age groups

Contacts

Primary Contactrachel heffez ayzenfeld, MD
rachelhe2@clalit.org.il09 7472185

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026